UK cost agency says 'no' to Celgene bone marrow drug
LONDON (Reuters) - Celgene's drug Revlimid is not worth using on Britain's state health service because of uncertainty over whether it can extend the lives of patients with serious bone marrow disorders, the country's cost agency said on Thursday.
The draft guidance from the National Institute for Health and Clinical Excellence (NICE), if confirmed following a consultation process, would remove a treatment option for patients with myelodysplastic syndromes, which can lead to life-threatening diseases such as leukemia.
(Reporting by Ben Hirschler; Editing by Louise Heavens)
- Malaysia air probe finds scant evidence of attack: sources |
- Malaysia probes passenger backgrounds for clues on missing flight |
- Confrontation in Ukraine as diplomacy stalls |
- N.Korea using sophisticated means to avoid U.N. sanctions - U.N. report
- Exclusive: Chinese raw materials also found on U.S. B-1 bomber, F-16 jets